logo
Eaton and Siemens Energy Join Forces to Provide Power and Technology to Accelerate the Delivery of New Data Center Capacity

Eaton and Siemens Energy Join Forces to Provide Power and Technology to Accelerate the Delivery of New Data Center Capacity

Business Wire6 days ago

DUBLIN & BERLIN--(BUSINESS WIRE)--Intelligent power management company Eaton, and Siemens Energy, one of the world's leading energy technology companies, have announced a fast-track approach to building data centers with integrated onsite power. They will address urgent market needs by offering reliable grid-independent energy supplies and standardized modular systems to facilitate swift data center construction and deployment.
Eaton and Siemens Energy join forces to provide power and technology to accelerate the delivery of new data center capacity.
Share
The collaboration will enable simultaneous construction of data centers and associated on-site power generation with grid connection and the integration of renewables to meet regional regulatory requirements, if required. This will provide data center owners and developers with choices they don't have at present to enable them to build and run new data centers.
Siemens Energy's modular and scalable power plant concept is tailored to the specific needs of data center operators. The standard configuration generates 500 megawatts (MW) of electricity, featuring highly efficient SGT-800 gas turbines, redundancy and additional battery storage systems, ensuring the highest reliability. Based on its modular approach, the size of the plant can be scaled up and down. In the future, it can also operate in a carbon-neutral manner, provided hydrogen is available and part of the data center's sustainability strategy. The Siemens Energy concept also includes an optional emission-free clean air grid connection to be installed either during construction or as a retrofit. This feature would enable data centers to provide grid services.
Eaton will provide customers with electrical equipment such as medium voltage switchgear, low voltage switchgear, UPS, busways, structural support, racks and containment systems, engineering services and the software offerings needed to protect and enable IT loads from the medium-voltage grid to the chip and help accelerate building and commissioning data centers with skidded and modular designs.
Cyrille Brisson, global segment leader, Data Centers, Eaton, said: 'Our approach of letting customers pick the right balance of energy sources is very flexible and construction to start-up time is swift with options to reduce emissions in both the short and long term. Crucially, our approach offers data center owners and developers the opportunity to build capacity and bring it online fast in any location where they have land available that is close to gas, water and fiber.'
Andreas Pistauer, global head of sales, Siemens Energy's Gas Services Business Area, said: 'We offer hyperscalers, co-locators and investors a unique package, enabling them to reduce the time-to-market by up to two years in many places which leads to significant revenue gains. Our power plant design is built with redundancy, eliminating the need for backup diesel generators, and reducing CO 2 emissions by about 50 percent.'
About Eaton
Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace and mobility markets. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we're helping to solve the world's most urgent power management challenges and building a more sustainable society for people today and generations to come.
Founded in 1911, Eaton has continuously evolved to meet the changing and expanding needs of our stakeholders. With revenues of nearly $25 billion in 2024, the company serves customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.
About Siemens Energy
Siemens Energy is one of the world's leading energy technology companies. The company works with its customers and partners on energy systems for the future, thus supporting the transition to a more sustainable world. With its portfolio of products, solutions and services, Siemens Energy covers almost the entire energy value chain – from power and heat generation and transmission to storage. The portfolio includes conventional and renewable energy technology, such as gas and steam turbines, hybrid power plants operated with hydrogen, and power generators and transformers. Its wind power subsidiary Siemens Gamesa makes Siemens Energy a global market leader for renewable energies. An estimated one-sixth of the electricity generated worldwide is based on technologies from Siemens Energy. Siemens Energy employs around 101,000 people worldwide in more than 90 countries and generated revenue of €34.5 billion in fiscal year 2024.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AI Enthusiasts Invited to ABBYY Developer Conference to Showcase Their Best Innovations Powering the Intelligent Enterprise
AI Enthusiasts Invited to ABBYY Developer Conference to Showcase Their Best Innovations Powering the Intelligent Enterprise

Business Wire

timean hour ago

  • Business Wire

AI Enthusiasts Invited to ABBYY Developer Conference to Showcase Their Best Innovations Powering the Intelligent Enterprise

BENGALURU, India--(BUSINESS WIRE)--The AI Pulse by ABBYY Developer Conference returns to Bengaluru, India July 9-10, 2025, for the third annual hackathon competition. The free, two-day event will challenge assumptions about enterprise AI by showcasing how document AI and process intelligence are solving real business challenges with technical deep dives, innovative use cases, and collaborative sessions with an emphasis on measurable outcomes. What stood out most was how our partners combined ABBYY technology with other platforms to solve real business problems. That spirit of innovation and collaboration is what makes this event special. Share In addition to the hackathon, there will be a dedicated business track to equip enterprise leaders and center of excellence (CoE) architects with practical guidance on scaling automation, accelerating time to value through the ABBYY ecosystem, and building trust through responsible AI. Last year's competition saw projects ranging from invoice processing to onboarding workflows enhanced with generative AI. 'What stood out most was how our partners combined ABBYY technology with other platforms to solve real business problems. That spirit of innovation and collaboration is what makes this event special. This year, we're taking it a step further with dedicated tracks and extra recognition for the winners who truly push the boundaries with a customer-first approach,' commented Neil Murphy, Chief Revenue Officer at ABBYY. This year, prizes will be awarded for Best Overall App, Best Use of an ABBYY Product and Best Integration of 3 rd Party AI. Register for the competition at 'Since our first devcon three years ago, the level of sophistication and imagination using purpose-built AI for business-critical processes has surpassed all expectations. We're seeing challenges with document automation and process workflows eliminated, accuracy and time-to-value increase, and leadership teams more confident knowing they're using ABBYY AI,' commented Bruce Orcutt, Chief Marketing Officer at ABBYY. 'Whether you want to network, code or co-create, the ABBYY developer conference is where the future of AI and automation are shaped.' Don't miss the opportunity to explore ABBYY technology, learn new use cases in AI, or connect with peers and experts. Attendance to the AI Pulse by ABBYY Developer Conference is free, but seats are limited. Secure yours by registering today at or email DevCon_enquiries@ with any questions. Developers are also invited to attend the ABBYY Developers Discord community at About ABBYY ABBYY puts your information to work with purpose-built AI. We combine innovation and experience to transform data from business-critical documents into intelligent actionable outcomes in over 200 languages in real time. We are trusted by more than 10,000 companies globally, including many in the Fortune 500, to drive significant impact where it matters most: accelerating customer experience, operational excellence, and competitive advantage. ABBYY is a global company with headquarters in Austin, Texas and offices in 13 countries. For more information, visit and follow us on LinkedIn, Twitter, Facebook, and Instagram. ABBYY can either be a registered trademark or a trademark and can also be a logo, a company name (or part of it), or part of a product name of ABBYY group companies and may not be used without consent of its respective owners.

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

Yahoo

time2 hours ago

  • Yahoo

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

Business Wire

time3 hours ago

  • Business Wire

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store